{"prompt": "['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', '7. OUTCOME ASSESSMENTS', '7.1', 'Study Enppoints', 'Primary endpoints', 'Physician selection of Spectrum Therapeutics (ST) medical cannabis treatment regimen and', 'changes over time in:', '(1) average daily dose of THC and CBD (in mg);', '(2) route of administration (inhaled or ingested).', 'Secondary endpoints', 'Subject selection of ST treatment regimen and changes over time in:', '(1) average daily dose of THC and CBD (in mg);', '(2) route of administration (inhaled or ingested).', 'Change in BPI-SF responses from baseline.', 'Change in EQ5D-5L responses from baseline.', 'PGI-C for the target treatment goal.', 'CGI-I for the target treatment goal.', 'In subjects taking an opioid, changes in opioid use over time (calculated as milligram morphine', 'equivalents [MME]/day)', 'Among subjects taking other medication, total daily dose change over time.', 'Safety endpoint', 'Incidence of AEs stratified by product and formulation.', '7.2', 'Study Assessments', '7.2.1', 'EQ5D-5L- Euro QoL', 'EQ5D-5L is a 5-category questionnaire (with a total of 6 questions) assessing mobility, self-care, usual', 'activities, pain/discomfort, anxiety/depression, and overall health on a scale from 0-100 (where 100 denotes', 'the best, and 0 the worst health)28', '7.2.2', 'BPI-SF', 'The BPI-SF is a 9-item self-report questionnaire that is quickly and easily administered to subjects with', 'chronic pain. The questionnaire includes 6 pain items that assess the spatial and temporal characteristics of', 'pain (e.g., location, 24-hour worst pain, 24-hour average pain, pain ight now); 2 items that ask about current', 'treatments assumed for chronic pain and pain relief; and 1 pain interference item (with parts A-G) were', 'respondents rate the level of interference of pain with general activity, mood, walking ability, normal work,', 'social relations, sleep, and enjoyment of life over the past 24 hours24', '7.2.3', 'PGI-C', \"The PGI-C is a simple 1-item self-report outcome measure that assesses a subject's overall treatment\", 'satisfaction using a 7-point Likert-type scale. The PGI-C shows good performance and high responsiveness', 'in subjects with chronic pain and is often more responsive than primary measures of pain intensity, possibly', 'because the PGI-C captures additional elements of the analgesic response such as physical and', 'psychological functioning25.', '25 November 2020', 'CONFIDENTIAL', 'Page 22 of 79']['CANOPY GROWTH', 'Protocol #710-4502', '7.2.4', 'CGI-I', 'The CGI-I is a simple 1-item clinician-reported outcome measure, similar to the PGI-C, that assesses a', \"clinician's overall impression of subject improvement in response to treatment using a 7-point Likert-type\", 'scale. Although frequently used in clinical trials focused on mental disorders, the CGI has also been', 'evaluated in a context of chronic pain and correlates well with subject responses to the PGI-C26.', '7.2.5', 'Determination of Opioid Consumption', 'Physicians will confirm subjects who take an opioid at baseline or who start an opioid during the study, and', 'will be asked to report the opioid type and MME, so that opioid consumption (and any opioid-sparing effect', 'of the ST treatment regimen) can be examined over time.', '7.2.6', 'Other Concomitant Medications', 'Physicians will confirm subjects who take any non-opioid concomitant medication for pain at baseline, or', 'who start it during the study, and will be asked to report the medication type. The following medication', 'categories have been identified as common medication classes taken by chronic pain patients: Nonsteroidal', 'Anti-inflammatory Drugs (NSAIDs) and Acetaminophen, Antidepressants, Anticonvulsants,', 'Benzodiazepines and Muscle Relaxants. Physicians will be asked to report the medication type and total', 'daily dose, and any changes throughout the study.', '7.2.7', 'AEs/SAEs', 'All enrolled subjects and site physicians will receive guidance on AE reporting during the investigator', 'training. Spontaneous AE reporting will be entered in REDCap Cloud by the subject, during at-home', 'follow-up (subject to verification by physician at physician-verified follow-up). Physicians will classify', 'each AE by seriousness, severity and inferred relation to the study product in the Physician AE form as', 'described below. The GPVD will also review all SAEs with respect to applicable regulatory requirements.', '7.2.7.1', 'AE Definition', 'An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and which', 'does not necessarily have a causal relation with treatment. An AE can therefore be any unfavorable and', 'unintended sign, symptom, psychological effect, or disease associated with the use of a medicinal product,', 'whether or not related to the medicinal product.', '7.2.7.2', 'SAE Definition', 'An', 'AE will be considered serious if it results in 1 or more of the following outcomes:', 'Death', 'Life-threatening (i.e., at immediate risk of death)', 'Subject in-subject hospitalization or prolongation of existing hospitalization', 'Persistent or significant disability/incapacity', 'Congenital anomaly/birth defect', 'Any other AE that the Investigator or company judges to be serious or which is defined as serious by', 'the local regulatory agency.', 'Important AEs that may not result in death, be life threatening, or that do not require hospitalization may', 'be considered serious when, based upon appropriate medical judgment, they may jeopardize the subject or', 'may necessitate medical or surgical intervention to prevent one of the outcomes listed in the definition', 'above. For this registry, the Important Medical Event (IME) list will be used as a reference for the', 'assessment of medically significant adverse events30', '25 November 2020', 'CONFIDENTIAL', 'Page 23 of 79']\n\n###\n\n", "completion": "END"}